Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 12:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 882 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Period C Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Exercise in Health and Chronic Obstructive Pulmonary Disease

NCT02300064
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Knee-extensor exercise test, Exercise test with restricting/releasing blood flow, Exercise test with variable oxygen concentration and MRI, Exercise test with oral antioxidant or placebo cocktail
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Oct 31, 2026, 12:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Clinical Study to Assess the Effect of a Dietary Supplement on Menstrual Cycle Symptoms

NCT07267728
View directory record Official record
Conditions
Premenstrual Syndrome, Menstrual Pain
Interventions
DITTO Cycle Supplement
Dietary Supplement
Lead sponsor
Muse Nutrition Ltd
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 31, 2026, 12:58 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Beneficial Exposome Study

NCT06093464
View directory record Official record
Conditions
Healthy
Interventions
Natural Compound A (Hinoki essential oil), Natural Compound B (Lemon essential oil), Natural Compound C (Control/Water)
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 31, 2026, 12:58 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria

NCT05936567
View directory record Official record
Conditions
Urticaria, Chronic Spontaneous Urticaria, Chronic Idiopathic Urticaria, Hives, Angioedema, Pruritis
Interventions
Povorcitinib, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
22
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 31, 2026, 12:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Skin Surface and Intradermal Temperature Responses to Heat Stress

NCT06593067
View directory record Official record
Conditions
Hyperthermia
Interventions
Control, Fan, Fan and Water Spray, Water Spray
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 31, 2026, 12:58 PM EDT
Completed Not applicable Interventional Results available

Assessing 11C-Choline (11C-CH) PET to Distinguish True Tumor Progression From Pseudoprogression in High-grade Gliomas

NCT02849171
View directory record Official record
Conditions
Brain Cancer
Interventions
PET scan, C-Choline
Device · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Oct 31, 2026, 12:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults

NCT05319899
View directory record Official record
Conditions
Healthy
Interventions
ALXN1840, Omeprazole
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 31, 2026, 12:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Hepatitis B Virus (HBV) Prevention for Homeless at Risk for HBV/Hepatitis C Virus (HCV)/HIV

NCT00926146
View directory record Official record
Conditions
Hepatitis B, Hepatitis C, HIV, HIV Infections
Interventions
NCMIT, SCMIT
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 39 Years · Male only
Enrollment
451 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 31, 2026, 12:58 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

NCT02023879
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Placebo (for Alirocumab), Non-statin LMT, Diet Alone
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
8
States / cities
Beverly Hills, California • Atlantis, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2018 · Synced Oct 31, 2026, 12:58 PM EDT
Terminated Phase 1 Interventional

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS)

NCT04288856
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
BIIB078
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 31, 2026, 12:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioavailability and Effect of Food on TAK-385 Tablet Formulations in Healthy Participants

NCT02396147
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-385 T2 Formulation, TAK-385 T4 Formulation B, TAK-385 T4 Formulation C
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Oct 31, 2026, 12:58 PM EDT
Completed Phase 4 Interventional Results available

Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection

NCT03057847
View directory record Official record
Conditions
Hepatitis C, Chronic, Opioid-use Disorder
Interventions
Sofosbuvir/Velpatasvir
Drug
Lead sponsor
Elizabeth Krans, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 31, 2026, 12:58 PM EDT
Completed Phase 2 Interventional

Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor

NCT01356849
View directory record Official record
Conditions
Chronic Kidney Disease, Diabetic Nephropathy
Interventions
Atrasentan, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
59
States / cities
Pell City, Alabama • Tempe, Arizona • Azusa, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Oct 31, 2026, 12:58 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

ALPCO 25(OH) Vitamin D CLIA Kit - Fresh Versus Frozen Serum and Plasma Stability Study

NCT07565064
View directory record Official record
Conditions
Vitamin D Deficiency, Vitamin D Insufficiency, Healthy Volunteers
Interventions
ALPCO 25(OH) Vitamin D CLIA Kit
Device
Lead sponsor
American Laboratory Products Company
Industry
Eligibility
22 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Salem, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 31, 2026, 12:58 PM EDT
Completed Phase 2 Interventional Results available

Robotic Assisted Upper-Limb Neurorehabilitation in Stroke Patients

NCT00372411
View directory record Official record
Conditions
Stroke
Interventions
Robot-Assisted Therapy - MIT-MANUS System, Intensive Comparison Therapy, Usual Care
Device · Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
5
States / cities
West Haven, Connecticut • Gainesville, Florida • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 31, 2026, 12:58 PM EDT
Recruiting Not applicable Interventional

Telemedicine in Early Childhood Constraint Therapy in Cerebral Palsy

NCT04997109
View directory record Official record
Conditions
Cerebral Palsy
Interventions
APPLES-tele, Parent-centered Approach (PCA) Support Intervention, Standard of Care
Other · Behavioral
Lead sponsor
Emory University
Other
Eligibility
4 Months to 13 Months
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Atlanta, Georgia • Baltimore, Maryland • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 31, 2026, 12:58 PM EDT
Active, not recruiting Phase 2 Interventional

Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06290934
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
emvistegrast, Placebo-to-match emvistegrast
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
57
States / cities
Peoria, Arizona • Camarillo, California • Garden Grove, California + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 31, 2026, 12:58 PM EDT
Completed Not applicable Interventional Results available

Project CARE: An Integrated Treatment Adherence Program for Bipolar Disorder at the Time of Prison Release - Open Trial

NCT03825640
View directory record Official record
Conditions
Bipolar Disorder
Interventions
CARE
Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Cranston, Rhode Island • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 31, 2026, 12:58 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).

NCT05975905
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Dose A KER-012, Dose B KER-012, Dose C KER-012, Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks
Biological
Lead sponsor
Keros Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
16
States / cities
Scottsdale, Arizona • Tucson, Arizona • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 31, 2026, 12:58 PM EDT
Completed Phase 1 Interventional

A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis

NCT00676156
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
oral lipoic acid (LA), lipoic acid (LA) with fish oil and LA without fish oil, R lipoic acid
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Oct 31, 2026, 12:58 PM EDT
Completed Phase 2 Interventional Results available

Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)

NCT00078403
View directory record Official record
Conditions
HIV Infections, Hepatitis C, Liver Disease
Interventions
Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
36
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 31, 2026, 12:58 PM EDT
Completed Phase 3 Interventional

Whole-Body Cooling for Birth Asphyxia in Term Infants

NCT00005772
View directory record Official record
Conditions
Infant, Newborn, Hypoxia-Ischemia, Brain
Interventions
Induced hypothermia, Control
Device
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 6 Hours
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
16
States / cities
Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 31, 2026, 12:58 PM EDT
Completed Phase 2 Interventional Results available

Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC

NCT00828841
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Cetuximab, Paclitaxel, Carboplatin, Gemcitabine, Cisplatin
Drug
Lead sponsor
Accelerated Community Oncology Research Network
Other
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
84
States / cities
Anniston, Alabama • Jonesboro, Arkansas • Anaheim, California + 81 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Oct 31, 2026, 12:58 PM EDT
Completed Phase 2 Interventional

A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease

NCT07132983
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Ensifentrine 3 mg, Glycopyrrolate 42.5 mcg, Ensifentrine 1.5 mg, Ensifentrine 3 mg (marketed formulation)
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
4
States / cities
Clearwater, Florida • Tampa, Florida • Saint Charles, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 31, 2026, 12:58 PM EDT